Back to Search Start Over

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer.

Authors :
Heath, Elisabeth
Heilbrun, Lance
Mannuel, Heather
Liu, Glenn
Lara, Primo
Monk, J. Paul
Flaig, Thomas
Zurita, Amado
Mack, Philip
Vaishampayan, Ulka
Stella, Philip
Smith, Daryn
Bolton, Susan
Hussain, Arif
Al‐Janadi, Anas
Silbiger, Daniel
Usman, Muhammad
Ivy, S. Percy
Source :
Oncologist; Sep2019, Vol. 24 Issue 9, p1149-1149, 1p, 1 Diagram, 14 Charts, 2 Graphs
Publication Year :
2019

Abstract

<i>Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)

Details

Language :
English
ISSN :
10837159
Volume :
24
Issue :
9
Database :
Complementary Index
Journal :
Oncologist
Publication Type :
Academic Journal
Accession number :
138543113
Full Text :
https://doi.org/10.1634/theoncologist.2019-0331